Results 51 to 60 of about 13,066 (196)

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source

Hemoglobinúria paroxística noturna e gravidez Paroxysmal nocturnal hemoglobinuria in pregnancy

Revista Brasileira de Ginecologia e Obstetrícia, 2004
A hemoglobinúria paroxística noturna é doença rara, causada por mutação adquirida de um gene no sistema hematopoético com 16-18% dos casos diagnosticados durante a gravidez.
Marcelo Luís Nomura, Fernanda Garanhani de Castro Surita, Mary Angela Parpinelli, Egle Cristina Couto Carvalho, Renato Passini Júnior   +4 more
doaj   +1 more source

Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization during Diseases. [PDF]

, 2016
Chemokines are small chemotactic molecules that play key roles in physiological and pathological conditions. Upon signaling via their specific receptors, chemokines regulate tissue mobilization and trafficking of a wide array of immune cells, including ...
Ali, Allegretti, Balabanian, Berahovich, Bernardini, Bernardini, Bielekova, Bolomsky, Bradfield, Broxmeyer, Burga, Calderon, Campbell, Campbell, Carlsten, Carrega, Carrega, Castriconi, Chan, Chiossone, Chuang, Clift, Contento, Cooper, Doncker, Eisenhardt, El-Sherbiny, Fehniger, Foxman, Gajewski, Gao, Gomez-Mouton, Gregoire, Gulino, Halama, Hanna, Hayakawa, Huntington, Huntington, Inngjerdingen, Ishibashi, Ju, Juelke, Kastrukoff, Kramp, Krug, Krumbholz, Lanier, Lode, Lopez-Verges, Lunemann, Mace, Maciejewski-Duval, Mailliard, Mantovani, Marcenaro, Marquardt, Martin, Martin-Fontecha, Martinez-Rodriguez, Mayol, Moustaki, Muller, Nagasawa, Nakashima, Nokihara, Ottaviani, Ouyang, O’Boyle, Pablos, Pachynski, Pak-Wittel, Parolini, Paust, Petit, Ponzetta, Ponzetta, Riva, Rodriguez-Martin, Romagnani, Sciume, Sechler, Serrano-Pertierra, Shimoda, Sohy, Sojka, Somanchi, Stabile, Stegmann, Stumm, Szpurka, Tham, Vanbervliet, Vandenbark, Vischer, Vitale, Watt, Watts, Wendel, Yokoyama, Zabel, Zlotnik   +101 more
core   +1 more source

Patient‐Reported Oral Symptoms and Their Impact on Well‐Being After Haematopoietic Cell Transplantation

Oral Diseases, EarlyView.
ABSTRACT Objective Oral complications may negatively influence outcomes of haematopoietic cell transplantation (HCT). A comprehensive view of oral symptoms and symptom burden post‐HCT is lacking. This study aimed to determine the prevalence, severity, and temporal relationships of oral symptoms and their impact on well‐being in the early post‐HCT phase.
Kristina Skallsjö, Michael T. Brennan, Bengt Hasséus, Jenny Öhman, Judith E. Raber‐Durlacher, Marie‐Charlotte D. N. J. M. Huysmans, Alexa M. G. A. Laheij, Stephanie J. M. van Leeuwen, Allan J. Hovan, Karin Garming Legert, Scott Isom, David M. Kline, Nicole M. A. Blijlevens, Jan‐Erik Johansson, Inger von Bültzingslöwen   +14 more
wiley   +1 more source

Successful treatment of acute kidney injury secondary to haeme nephropathy in paroxysmal nocturnal haemoglobinuria with alkaline diuresis [PDF]

, 2012
Paroxysmal nocturnal haemoglobinuria (PNH) also known as ‘Marchiafava Micheli syn-drome’ is a rare condition which can lead to both acute and chronic forms of renal failure through renal tubular haemosiderin deposition. A 45-year-old lady with underlying
Das, S., Fadilah, S.A.W., Sakthiswary, R.   +2 more
core  

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis : a subgroup analysis of the REGAIN open-label extension study [PDF]

, 2019
The terminal complement inhibitor eculizumab was shown to improve myasthenia gravis-related symptoms in the 26-week, phase 3, randomized, double-blind, placebo-controlled REGAIN study (NCT01997229).
De Bleecker, Jan, Fujita, KP, Imai, T, Murai, H, O'Brien, F, Okumura, M, Shiraishi, H, Study Group, REGAIN, Suzuki, H, Suzuki, Y, Utsugisawa, K, Uzawa, A, Wang, JJ   +12 more
core   +1 more source

Hetrombopag Added to Cyclosporine as the First‐Line Treatment for Patients With Non‐Severe Aplastic Anemia: A Phase 2 Multicenter Trial

American Journal of Hematology, Volume 101, Issue 3, Page 467-476, March 2026.
ABSTRACT Non‐severe aplastic anemia (NSAA) is a heterogeneous bone marrow failure syndrome with limited standardized treatment options. Cyclosporine A (CsA) monotherapy often yields suboptimal responses, highlighting an unmet clinical need for more effective therapies.
Lele Zhang, Ruonan Li, Qian Liang, Weiwang Li, Hong Pan, Zhen Gao, Liwei Fang, Jingyu Zhao, Xiao Yu, Zhexiang Kuang, Neng Nie, Jianping Li, Jinbo Huang, Xin Zhao, Meili Ge, Yizhou Zheng, Jun Li, Hong Zhang, Jun Shi   +18 more
wiley   +1 more source

The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells

Haematologica, 2012
Background Patients with paroxysmal nocturnal hemoglobinuria harbor clonal glycosylphosphatidylinositol-anchor deficient cells arising from a multipotent hematopoietic stem cell acquiring a PIG-A mutation.
Jeffrey J. Pu, Rong Hu, Galina L. Mukhina, Hetty E. Carraway, Michael A. McDevitt, Robert A. Brodsky   +5 more
doaj   +1 more source

Intravascular Large B-Cell Lymphoma Presenting as Dementia and Hemolytic Anemia [PDF]

, 2010
Background: Intravascular lymphoma (IVL) is an uncommon disease characterized by atypical lymphoid cells growing inside the lumina of small vessels. The diversity of clinical presentation due to possible involvement of multiple organs often complicates ...
Ahle, Guido, Baraniskin, Alexander, Jähnert, Andreas, Kretzschmar, Hans, Schmiegel, Wolff, Schroers, Roland, Theile, Anja   +6 more
core   +1 more source

Iptacopan for Immune Thrombocytopenia and Cold Agglutinin Disease: A Global Phase 2 Basket Clinical Trial

American Journal of Hematology, Volume 101, Issue 2, Page 242-254, February 2026.
ABSTRACT Iptacopan is a first‐in‐class, oral, selective inhibitor of complement factor B that has demonstrated positive efficacy across several complement‐driven diseases. Here we evaluate the efficacy and safety of iptacopan monotherapy in adult patients with primary immune thrombocytopenia (ITP) and primary cold agglutinin disease (CAD). We performed
Alexander Röth, Wilma Barcellini, Christine Ademokun, Junho Jang, Maria Luisa Lozano, David Valcarcel Ferreiras, Cristina Pascual‐Izquierdo, Shripad Chitnis, Sofiya Matviykiv, Alessandra Vitaliti, Chi Chen, Vasiliki Katsanou, Raghav Chawla, Hanny Al‐Samkari   +13 more
wiley   +1 more source